ClinicalTrials.gg
Active, not recruitingNCT03073785Updated Nov 4, 2026Results posted

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

A Phase 2 interventional study of Capecitabine and Fluorouracil in Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma and Stage I Pancreatic Cancer AJCC v6 and v7, sponsored by University of Nebraska. Active, not recruiting at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by University of Nebraska · Phase 2, Interventional, and Treatment

How we know

Updated Nov 4, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
658th of 1,573
46 · median 37
Started
2017
with 100 others
Phase 2
488 of 1,850
45 open now
Primary completion
2023-12
later than 23 of 468 live
Registered
1,032nd of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 658th largest by enrollment of the 1,573 interventional ones that give a count, is one of 101 that started in 2017, is one of 488 in phase 2, reaches primary completion later than 23 of the 468 other live ones, and was the 1,032nd registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

292 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Pancreatic cancer, most commonly adenocarcinoma, is the fourth leading cause of cancer death in the United States. The mainstay of management centers on surgical resection (if resectable) and although low (15% to 20%), resectability rates are associated with dismal survival. An estimated 80% to 85% of the patients recur after surgical resection, leading to a median survival of 20 to 24 months and potentially even less depending on lymph nodal involvement or positive margins. The rationale for utilizing neoadjuvant therapy, commonly fluoropyrimidine-based or gemcitabine based chemotherapy or Chemoradiotherapy (CRT), involves possibly down staging borderline resectable and unresectable patients, potentially making them resectable candidates.

This randomized phase II trial will study how well hypofractionated stereotactic body radiation therapy (SBRT) and fluorouracil or capecitabine with or without zoledronic acid work in treating participants with pancreatic cancer that has spread to nearby tissue or lymph nodes. Hypofractionated stereotactic body radiation therapy is a specialized radiation therapy that sends higher doses of x-rays over a shorter period of time directly to the tumor using smaller doses over several days which may cause less damage to normal tissue. Drugs used in chemotherapy, such as fluorouracil and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Zoledronic acid is used in cancer patients to reduce cancer symptoms and may make tumor cells more sensitive to radiation. Giving hypofractionated stereotactic body radiation therapy and fluorouracil or capecitabine with or without zoledronic acid may work better in treating pancreatic cancer.

Read the detailed description

Pancreatic cancer, most commonly adenocarcinoma, is the fourth leading cause of cancer death in the United States. The mainstay of management centers on surgical resection (if resectable) and although low (15% to 20%), resectability rates are associated with dismal survival. An estimated 80% to 85% of the patients recur after surgical resection, leading to a median survival of 20 to 24 months and potentially even less depending on lymph nodal involvement or positive margins. The rationale for utilizing neoadjuvant therapy, commonly fluoropyrimidine-based or gemcitabine based chemotherapy or Chemoradiotherapy (CRT), involves possibly down staging borderline resectable and unresectable patients, potentially making them resectable candidates.

This randomized phase II trial will study how well hypofractionated stereotactic body radiation therapy (SBRT) and fluorouracil or capecitabine with or without zoledronic acid work in treating participants with pancreatic cancer that has spread to nearby tissue or lymph nodes. Hypofractionated stereotactic body radiation therapy is a specialized radiation therapy that sends higher doses of x-rays over a shorter period of time directly to the tumor using smaller doses over several days which may cause less damage to normal tissue. Drugs used in chemotherapy, such as fluorouracil and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Zoledronic acid is used in cancer patients to reduce cancer symptoms and may make tumor cells more sensitive to radiation. Giving hypofractionated stereotactic body radiation therapy and fluorouracil or capecitabine with or without zoledronic acid may work better in treating pancreatic cancer.

The primary study objective is to evaluate the efficacy of hypofractionated radiation therapy concurrently with zoledronic acid (Zometa) and fluorouracil or capecitabine. Other study objectives include examining the toxicity of Zometa when used concurrently with hypofractionated radiation therapy, evaluating local failure-free survival and overall survival, determining surgical resection and tumor response rates, measuring Zometa pharmacokinetics, evaluating tumor and organ motion and determining the effect those on the dosimetry, local control and survival. Post-treatment follow-up is for 30 days, then every 3 months for the first year, every 4 months for the second year, and every 6 months thereafter.

03

Conditions studied

  • Pancreatic Adenocarcinoma
  • Recurrent Pancreatic Carcinoma
  • Stage I Pancreatic Cancer AJCC v6 and v7
  • Stage IA Pancreatic Cancer AJCC v6 and v7
  • Stage IB Pancreatic Cancer AJCC v6 and v7
  • Stage II Pancreatic Cancer AJCC v6 and v7
  • Stage IIA Pancreatic Cancer AJCC v6 and v7
  • Stage IIB Pancreatic Cancer AJCC v6 and v7
  • Stage III Pancreatic Cancer AJCC v6 and v7
  • Stage IV Pancreatic Cancer AJCC v6 and v7
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed pancreatic adenocarcinoma, either initially diagnosed or recurrent locally advanced disease. The maximum dimension of the treatment target must be =\<10 cm. Locally advanced disease defined as: T 1-2N+MO or T3-4 NxMo, or borderline resectable and unresectable adenocarcinoma without distant disease or resectable T3-4 NxMo disease or M1 with controlled distant disease
  • Inoperable conditions with resectable disease (T1-2NoMo)
  • performance status of 60% or better. Received recent chemotherapy for pancreatic cancer or completed chemotherapy > 5 years ago for other than pancreatic cancer with no evidence of the second malignancy at study entry
  • Radiation therapy completed > 5 years ago for malignancies other than pancreatic cancer and whose radiation therapy field is not overlapping with the 20% isodose line of current radiation field and no evidence of the second malignancy at study entry
  • All malignant disease must be able to be encompassed within a single irradiation field
  • (ANC) greater than or equal to 1500/uL
  • Radiographically assessable disease
  • count greater than or equal to 100,000/uL
  • Serum creatinine less than or equal to 2.0 mg/dL and total less than or equal to 2.0 mg/dL in the absence of biliary obstruction. If biliary obstruction is present, biliary decompression will be required, either endoscopic placement of a biliary stent or percutaneous transhepatic. Once biliary drainage has been established, institution of protocol therapy may proceed when the total bilirubin falls to 4.0 mg/dL or lower
  • Calculated of >= 35.
  • Awareness of the neoplastic nature of his/her disease and willingly provide written, after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts

Exclusion criteria

Exclusion Criteria:

  • Known allergy to Zometa or to anti-emetics appropriate in conjunction with protocol-directed therapy
  • Uncontrolled inter-current illness that might jeopardize the ability of the subject to receive the protocol therapy with reasonable safety. This may include, but not limited to, ongoing or active infection requiring intravenous antibiotics, symptomatic congestive heart failure, unstable angina pectoris, or serious, uncontrolled cardiac arrhythmia
  • Pregnant and nursing women
  • Prior except adequately treated basal cell or squamous cell skin cancer, adequately treated non-invasive carcinomas, or be disease-free for at least 5 years from other cancers
  • Active duodenal ulcer or bleeding or history of a gastrointestinal fistula or perforation or other significant bowel problems (severe nausea, vomiting, inflammatory bowel disease and significant bowel resection)
  • Known (HIV) infection, or hepatic insufficiency
  • Not currently receiving or have received Zometa within 3 weeks prior to study treatment with Zometa
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Active comparator
    Arm A (chemotherapy, radiation therapy)

    Participants undergo hypofractionated stereotactic body radiation therapy in 5 fractions on days 1-5. Participants receive fluorouracil IV over 24 hours on day 1 weekly for 4 weeks or capecitabine by mouth every 12 hours starting the evening before day 1 of radiation therapy for 4 weeks as per standard of care. Participants then undergo surgery 6-8 weeks after completion of radiation therapy.

    Drug: Capecitabine · Drug: Fluorouracil · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study · Radiation: Stereotactic Body Radiation Therapy

  • Experimental
    Arm B (zoledronic acid, chemotherapy, radiation therapy)

    Participants receive zoledronic acid IV over a minimum of 15 minutes 1 week prior to radiation therapy. Participants undergo hypofractionated stereotactic body radiation therapy and receive treatment with fluorouracil IV or capecitabine by mouth as in Arm A. Participants then undergo surgery 6-8 weeks after completion of radiation therapy.

    Drug: Capecitabine · Drug: Fluorouracil · Other: Laboratory Biomarker Analysis · Other: Pharmacological Study · Radiation: Stereotactic Body Radiation Therapy · Drug: Zoledronic Acid

Interventions

  • Given by mouth (PO)

    Also known as: Ro 09-1978/000, Xeloda

  • Given Intravenously (IV)

    Also known as: 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • OtherPharmacological Study

    Correlative studies

  • RadiationStereotactic Body Radiation Therapy

    Undergo hypofractionated stereotactic radiotherapy

    Also known as: SABR, SBRT, Stereotactic Ablative Body Radiation Therapy

  • Given IV

    Also known as: [1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic Acid, CGP 42446, CGP42446A, NDC-Zoledronate, Reclast, ZOL 446, Zometa

06

What researchers measure

Primary outcomes

  1. Local Control With and Without Zometa at Four Months in Follow-up

    Local control will be assessed using three-dimensional (3D) computed tomography (CT). The primary tumor will be contoured using Varian planning software, and tumor volume will be measured at baseline and at 4 months post-treatment. Local control is defined as absence of disease progression, with progression defined as a ≥25% increase in tumor volume. Tumor response will also be assessed using RECIST-based criteria (≥20% increase in tumor diameter) as a supportive analysis.

    Time frame: At 4 months in follow-up

  2. Local Control With and Without Zometa at Eight Months in Follow-up

    Local control will be assessed using three-dimensional (3D) computed tomography (CT). The primary tumor will be contoured using Varian planning software, and tumor volume will be measured at baseline and at 8 months post-treatment. Local control is defined as absence of disease progression, with progression defined as a ≥25% increase in tumor volume. Tumor response will also be assessed using RECIST-based criteria (≥20% increase in tumor diameter) as a supportive analysis.

    Time frame: At 8 months in follow-up

  3. Local Control With and Without Zometa at Twelve Months in Follow-up

    Local control will be assessed using three-dimensional (3D) computed tomography (CT). The primary tumor will be contoured using Varian planning software, and tumor volume will be measured at baseline and at 12 months post-treatment. Local control is defined as absence of disease progression, with progression defined as a ≥25% increase in tumor volume. Tumor response will also be assessed using RECIST-based criteria (≥20% increase in tumor diameter) as a supportive analysis.

    Time frame: At 12 months in follow-up

Secondary outcomes

  1. Grade 3 and Above Adverse Events With and Without Zoledronic Acid

    Grade 3 and above adverse events (AE) will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.

    Time frame: Up to 30 days after treatment

  2. Failure-free Survival With and Without Zometa

    Time to any failure (disease progression or recurrence determined by imaging, or death) will be analyzed using Kaplan-Meier method between participants receiving Zometa and those who don't.

    Time frame: From date of administration of study drug to the date of any failure, assessed up to 5 years

  3. Overall Survival With and Without Zometa

    Time to death will be analyzed using Kaplan-Meier method between participants receiving Zometa and those who don't.

    Time frame: From date of administration of study drug to the date of death, assessed up to 5 years

  4. Surgically Complete Resection Rate With and Without Zometa

    The number and proportion of participants undergoing complete resection (negative margin) will be determined between participants receiving Zometa and those who don't.

    Time frame: Immediately after surgery

  5. Pathologic Response After Resection With and Without Zometa

    The pathologic response will be scored from 0-9 by a pathologist, 0 is no response and 9 is complete response between participants receiving Zometa and those who don't.

    Time frame: Immediately after surgery

  6. All-Cause Mortality

    All anticipated and unanticipated deaths due to any cause

    Time frame: From date of administration of study drug to the date of death, assessed up to 10 years

07

Results

Posted Nov 4, 2026
Limitations and caveats
Several limitations should be considered. The sample size was modest, and the study was not powered for definitive comparisons between treatment arms. Early trial closure and heterogeneity in induction chemotherapy regimens may have further limited statistical power.

Participant flow

Participant flow — Overall Study
MilestoneArm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)
Started2323
Completed2220
Not completed13

Outcome measures

PrimaryLocal Control With and Without Zometa at Four Months in Follow-up

Local control will be assessed using three-dimensional (3D) computed tomography (CT). The primary tumor will be contoured using Varian planning software, and tumor volume will be measured at baseline and at 4 months post-treatment. Local control is defined as absence of disease progression, with progression defined as a ≥25% increase in tumor volume. Tumor response will also be assessed using RECIST-based criteria (≥20% increase in tumor diameter) as a supportive analysis.

Time frame:
At 4 months in follow-up
Reported as:
Number · participants
Local Control With and Without Zometa at Four Months in Follow-up
participantsArm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)
Local Control With and Without Zometa at Four Months in Follow-up2219
PrimaryLocal Control With and Without Zometa at Eight Months in Follow-up

Local control will be assessed using three-dimensional (3D) computed tomography (CT). The primary tumor will be contoured using Varian planning software, and tumor volume will be measured at baseline and at 8 months post-treatment. Local control is defined as absence of disease progression, with progression defined as a ≥25% increase in tumor volume. Tumor response will also be assessed using RECIST-based criteria (≥20% increase in tumor diameter) as a supportive analysis.

Time frame:
At 8 months in follow-up
Reported as:
Number · participants
Local Control With and Without Zometa at Eight Months in Follow-up
participantsArm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)
Local Control With and Without Zometa at Eight Months in Follow-up1918
PrimaryLocal Control With and Without Zometa at Twelve Months in Follow-up

Local control will be assessed using three-dimensional (3D) computed tomography (CT). The primary tumor will be contoured using Varian planning software, and tumor volume will be measured at baseline and at 12 months post-treatment. Local control is defined as absence of disease progression, with progression defined as a ≥25% increase in tumor volume. Tumor response will also be assessed using RECIST-based criteria (≥20% increase in tumor diameter) as a supportive analysis.

Time frame:
At 12 months in follow-up
Reported as:
Number · participants
Local Control With and Without Zometa at Twelve Months in Follow-up
participantsArm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)
Local Control With and Without Zometa at Twelve Months in Follow-up1917
SecondaryGrade 3 and Above Adverse Events With and Without Zoledronic Acid

Grade 3 and above adverse events (AE) will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.

Time frame:
Up to 30 days after treatment
Reported as:
Number · participants
Grade 3 and Above Adverse Events With and Without Zoledronic Acid
participantsArm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)
Grade 3 and Above Adverse Events With and Without Zoledronic Acid76
SecondaryFailure-free Survival With and Without Zometa

Time to any failure (disease progression or recurrence determined by imaging, or death) will be analyzed using Kaplan-Meier method between participants receiving Zometa and those who don't.

Time frame:
From date of administration of study drug to the date of any failure, assessed up to 5 years
Reported as:
Median · Month
Failure-free Survival With and Without Zometa
MonthArm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)
Failure-free Survival With and Without Zometa11 (6.1 to 18.5)8 (2.4 to 13.6)
SecondaryOverall Survival With and Without Zometa

Time to death will be analyzed using Kaplan-Meier method between participants receiving Zometa and those who don't.

Time frame:
From date of administration of study drug to the date of death, assessed up to 5 years
Reported as:
Median · Month
Overall Survival With and Without Zometa
MonthArm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)
Overall Survival With and Without Zometa23.9 (11.5 to 30)26.1 (9 to 35.3)
SecondarySurgically Complete Resection Rate With and Without Zometa

The number and proportion of participants undergoing complete resection (negative margin) will be determined between participants receiving Zometa and those who don't.

Time frame:
Immediately after surgery
Reported as:
Count of participants · Participants
Surgically Complete Resection Rate With and Without Zometa
ParticipantsArm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)
Surgically Complete Resection Rate With and Without Zometa98
SecondaryPathologic Response After Resection With and Without Zometa

The pathologic response will be scored from 0-9 by a pathologist, 0 is no response and 9 is complete response between participants receiving Zometa and those who don't.

Time frame:
Immediately after surgery
Reported as:
Median · score
Pathologic Response After Resection With and Without Zometa
scoreArm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)
Pathologic Response After Resection With and Without Zometa4 (3 to 7)4 (3 to 9)
SecondaryAll-Cause Mortality

All anticipated and unanticipated deaths due to any cause

Time frame:
From date of administration of study drug to the date of death, assessed up to 10 years

Results for this outcome have not been posted.

Adverse events

Collected over For each participant, adverse events were collected from the time of informed consent until 30 days after the last study treatment (a combination of RT, chemotherapy, and surgery if applicable). If subjects did not have surgery, it was 30 days post-capecitabine cessation. Adverse event data was collected over 6 years for all participants.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A (Chemotherapy, Radiation Therapy)20/22 (90.9%)4/22 (18.2%)21/22 (95.5%)
Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)16/20 (80%)2/20 (10%)19/20 (95%)
Most frequent serious events
Most frequent serious events
EventArm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)
FallInjury, poisoning and procedural complications0/221/20
Lung infectionInfections and infestations0/221/20
SomnolenceNervous system disorders0/221/20
Aspartate aminotransferase increasedInvestigations1/220/20
AnorexiaMetabolism and nutrition disorders1/220/20
DehydrationMetabolism and nutrition disorders1/220/20
Hepatobiliary disorders - Other, specifyHepatobiliary disorders1/220/20
Venous InjuryInjury, poisoning and procedural complications1/220/20
Wound complicationInjury, poisoning and procedural complications1/220/20
Most frequent other events
Showing 10 of 69
Most frequent other events
EventArm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)
DiarrheaGastrointestinal disorders2/229/20
FatigueGeneral disorders8/229/20
NauseaGastrointestinal disorders9/228/20
Aspartate aminotransferase increasedInvestigations8/222/20
Platelet count decreasedInvestigations6/227/20
White blood cell decreasedInvestigations6/227/20
HypocalcemiaMetabolism and nutrition disorders5/226/20
Alanine aminotransferase increasedInvestigations6/221/20
Alkaline phosphatase increasedInvestigations6/224/20
AnemiaBlood and lymphatic system disorders6/225/20

Baseline characteristics

Age, Continuous
Age, Continuous(year)Arm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)Total
Median65 (44 to 81)64 (48 to 75)64.5 (44 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Arm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)Total
Female8816
Male141226
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American000
White212041
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Arm A (Chemotherapy, Radiation Therapy)Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy)Total
United States222042
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Dec 2023, 80 months.

Results were first posted in Nov 2026, 2 years 10 months after primary completion.

Of 327 non-industry phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 80. This study's 80 months is above that.

Counting every sponsor, half of 396 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Sep 2016 → Mar 2017 and primary completion Dec 2027 → Dec 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2017
First posted
Mar 8, 2017
StartActual
Mar 23, 2017was Sep 2016
Primary completionActual
Dec 12, 2023was Dec 2027
CompletionEst.
Dec 2027
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Start date
Sep 16, 2016→Mar 23, 2017
Nov 4, 2026
Primary completion
Dec 2027→Dec 12, 2023 (actual)
Nov 4, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedLocal controlControl With and Without Zometa at Four Months in Follow-upTime frame: At 4 months in follow-up
  • EditedLocal controlControl With and Without Zometa at Eight Months in Follow-upTime frame: At 8 months in follow-up
  • EditedLocal controlControl With and Without Zometa at Twelve Months in Follow-upTime frame: At 12 months in follow-up
Nov 4, 2026
Secondary outcomes
1 edited, 2 added, 6 removed
What changed in the outcomes
  • EditedLocal Failure-free Survival With and Without ZometaTime frame: From date of administration of study drug to the date of local failure, assessed up to 5 years → From date of administration of study drug to the date of any failure, assessed up to 5 years
  • AddedGrade 3 and Above Adverse Events With and Without Zoledronic AcidTime frame: Up to 30 days after treatment
  • AddedAll-Cause MortalityTime frame: From date of administration of study drug to the date of death, assessed up to 10 years
  • RemovedMaximum Tolerated Dose of Zoledronic AcidTime frame: Up to 30 days after surgery
  • RemovedChange in Tumor Size after Stereotactic Body Radiation Therapy With and Without ZometaTime frame: Within 1 month prior to SBRT and 4-5 weeks after SBRT
  • RemovedChange of maximum and average Standardized Uptake Values after Stereotactic Body Radiation Therapy With and Without ZometaTime frame: Within 1 month prior to SBRT and 4-5 weeks after SBRT
  • RemovedTumor and Organ MotionTime frame: Immediately prior to stereotactic body radiation therapy (SBRT)
  • Removedother outcomeRNA Sequence Assessment of Gene Expression of Cholesterol Biosynthesis for Resection With or Without ZometaTime frame: Up to 5 years
  • Removedother outcomePharmacokinetics of Zoledronic AcidTime frame: At 0 and 1 hours post-zoledronic acid dose, and before stereotactic body radiation therapy (SBRT) treatments on days 2, 3, 4, and 5
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Start date Sep 16, 2016→Mar 23, 2017
    Primary completion Dec 2027→Dec 12, 2023 (now actual)
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedLocal controlControl With and Without Zometa at Four Months in Follow-upTime frame: At 4 months in follow-up
    • EditedLocal controlControl With and Without Zometa at Eight Months in Follow-upTime frame: At 8 months in follow-up
    • EditedLocal controlControl With and Without Zometa at Twelve Months in Follow-upTime frame: At 12 months in follow-up
    Secondary outcomes 1 edited, 2 added, 6 removed
    What changed in the outcomes
    • EditedLocal Failure-free Survival With and Without ZometaTime frame: From date of administration of study drug to the date of local failure, assessed up to 5 years → From date of administration of study drug to the date of any failure, assessed up to 5 years
    • AddedGrade 3 and Above Adverse Events With and Without Zoledronic AcidTime frame: Up to 30 days after treatment
    • AddedAll-Cause MortalityTime frame: From date of administration of study drug to the date of death, assessed up to 10 years
    • RemovedMaximum Tolerated Dose of Zoledronic AcidTime frame: Up to 30 days after surgery
    • RemovedChange in Tumor Size after Stereotactic Body Radiation Therapy With and Without ZometaTime frame: Within 1 month prior to SBRT and 4-5 weeks after SBRT
    • RemovedChange of maximum and average Standardized Uptake Values after Stereotactic Body Radiation Therapy With and Without ZometaTime frame: Within 1 month prior to SBRT and 4-5 weeks after SBRT
    • RemovedTumor and Organ MotionTime frame: Immediately prior to stereotactic body radiation therapy (SBRT)
    • Removedother outcomeRNA Sequence Assessment of Gene Expression of Cholesterol Biosynthesis for Resection With or Without ZometaTime frame: Up to 5 years
    • Removedother outcomePharmacokinetics of Zoledronic AcidTime frame: At 0 and 1 hours post-zoledronic acid dose, and before stereotactic body radiation therapy (SBRT) treatments on days 2, 3, 4, and 5
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03073785
Responsible party
Sponsor
First posted
Mar 8, 2017
Start date
Mar 23, 2017
Primary completion
Dec 12, 2023
Completion
Dec 2027 (estimated)
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Chi Lin, MD, PhD
principal investigator · University of Nebraska

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zoledronic Acid

Start the discussion